Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial-Reference-Cited by-同舟云学术

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial

Published:2020-08-07 Issue:11 Volume:22 Page:2077-2088
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Mosenzon Ofri¹^ORCID,Bain Stephen C.²^ORCID,Heerspink Hiddo J. L.³⁴^ORCID,Idorn Thomas⁵,Mann Johannes F. E.⁶⁷,Persson Frederik⁸^ORCID,Pratley Richard E.⁹,Rasmussen Søren⁵,Rossing Peter⁸¹⁰,von Scholten Bernt Johan⁵,Raz Itamar¹^ORCID,

Affiliation:

1. Diabetes Unit Hadassah Medical Center, Hebrew University of Jerusalem Jerusalem Israel

2. Diabetes Research Unit Cymru Swansea University Swansea UK

3. Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen Groningen the Netherlands

4. The George Institute for Global Health Sydney Australia

5. Novo Nordisk A/S Søborg Denmark

6. Department of Nephrology University Hospital, Friedrich Alexander University of Erlangen Erlangen Germany

7. KfH Kidney Center Munich Germany

8. Steno Diabetes Center Copenhagen Gentofte Denmark

9. AdventHealth Translational Research Institute Orlando Florida USA

10. Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14126

Reference42 articles.

1. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

2. Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals

3. Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes

4. KDIGO.KDIGO2012Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.https://kdigoorg/wp-content/uploads/2017/02/KDIGO_2012_CKD_GLpdf. Accessed February 2020.

5. Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study;Diabetes, Obesity and Metabolism;2024-08-07

2. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease;Kidney International;2024-08

3. Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis;Diabetes, Obesity and Metabolism;2024-07-17

4. The Cardiac-Kidney-Liver (CKL) syndrome: the “real entity” of type 2 diabetes mellitus;Archives of Medical Science;2024-01-31

5. Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review;Communications Medicine;2023-10-05